how do glp-1 drugs work for weight loss Agonists: Using Semaglutide, Tirzepatide, and Orforglipron and Obesity Weight loss drugs – hope

Cochrane Database Syst Rev 2012

News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al

Any score greater than 8 kPA on VCTE should be referred to Hepatology for further assessment

Safety and discontinuation rates are comparable to other GLP-1 drugs